Abstracts tagged "fibromyalgia and spondylarthritis"

Abstract Number: 1690 • 2015 ACR/ARHP Annual Meeting
Fibromyalgia in Spondyloarthritis: Impact on Disease Activity Assessment
Jean Wach, Marie-Claude Letroublon and Jacques G Tebib, Rheumatology, Hospices Civils de Lyon, Centre Hospitalier Lyon-Sud, Pierre-Bénite, France
Background/Purpose: Spondyloarthritis (SpA) is the second most frequent inflammatory rheumatic disease, which main manifestations are spinal pain and peripheral arthritis or enthesitis. Fibromyalgia (FM), a…
Abstract Number: 2599 • 2014 ACR/ARHP Annual Meeting
Do Patients Diagnosed As Axial Spondyloarthritis (AxSpA) Who Have Primary Inefficacy to Anti-TNF Really Have AxSpA? a Five-Year Follow-up Study of 27 Patients with Primary Inefficacy to Anti-TNF
Sandra Kossi¹, Sabrina Dadoun², Bruno Fautrel², Maxime Dougados³ and Laure Gossec⁴, ¹75, Hopital La Pitie Salpetrière, Paris, France, ²Rheumatology, UPMC GRC08, Paris 06 University, Pitié Salpétrière Hospital, Paris, France, ³INSERM (U1153): Clinical Epidemiology and Biostatistics, PRES Sorbonne Paris-Cité, Paris, France., Paris, France, ⁴Sorbonne Universités, UPMC Univ Paris 06, GRC-08, Institut Pierre Louis d’Epidémiologie et de Santé Publique, paris, France
Background/Purpose The diagnosis of AxSpA is not easy and there are cases of overlap with fibromyalgia for example. Anti-TNF have been shown to have great…
Abstract Number: 1558 • 2014 ACR/ARHP Annual Meeting
Evaluation of Extreme Enthesitis and/or Patient-Related Outcome Score As Potential Surrogates for Fibromyalgia and As Potential Confounding Factors of Anti-TNF Response
M Dougados¹, H Jones², A Szumski³, I Logeart⁴ and J Coindreau⁵, ¹Université Paris René Descartes and Hôpital Cochin, Paris, France, ²Inflammation & Immunology, Pfizer Inc., Collegeville, PA, ³Pfizer Inc., Collegeville, PA, ⁴Pfizer, Paris, France, ⁵Pfizer Inc., New York, NY
Background/Purpose: Differentiating between pain related to spondyloarthritis (in particular polyenthesitis) and pain related to fibromyalgia can be challenging, both in daily practice and in clinical…
Abstract Number: 1519 • 2013 ACR/ARHP Annual Meeting
Meeting The ACR 2010 Fibromyalgia Criteria Worsens Disease Activity and Quality Of Life In Patients With Axial Spondyloarthritis Treated With Infliximab
Mathieu Verdet¹, Clément Guillou², Julien Michaud¹, Christopher Banse¹, Sandra Desouches¹, Gilles Avenel³, Quentin Bréhier⁴, Aurélia Bisson-Vaivre¹, Sophie Pouplin¹ and Olivier Vittecoq⁵, ¹Rheumatology, Rouen University Hospital, Rouen, France, ²Inserm 905 & Institute for Biomedical Research, University of Rouen, Rouen, France, ³Rheumaotlogy, Rouen University Hospital, Rouen, France, ⁴Rheumatology, Le Havre Hospital, Le Havre, France, ⁵Rheumatology, Department of Rheumatology, Rouen University Hospital & Inserm 905, Institute for Biomedical Research, University of Rouen, Rouen, France
Background/Purpose: Managing axial spondyloarthritis (aSpA) may be difficult because sometimes patients are not good responder to anti-TNF. We made the hypothesis that in certain patients,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].